The American Kidney Fund (AKF) applauds the introduction of the federal Living Donor Protection Act of 2021 (H.R.1255/S.377), which would provide living organ donors important job protections while also protecting them from discrimination by life, disability and long-term care insurance carriers.
The federal legislation would provide a uniform baseline of protections nationwide for living organ donors. AKF’s State of the States: Living Donor Protection Report Card, released in February, found that the 50 states and the District of Columbia currently offer a patchwork of protections to living organ donors-meaning that where a person lives can affect their ability to be a living donor.
There are currently 108,000 people on the national transplant waiting list, including 93,000 who are waiting for a kidney. The bipartisan legislation was introduced in the House by Rep. Jerry Nadler (D-NY) and Rep. Jaime Herrera Beutler (R-Washington) and in the Senate by Sen. Kirsten Gillibrand (D-NY) and Sen. Tom Cotton (R-Arkansas).
“Passage of the federal Living Donor Protection Act would ultimately shorten the kidney transplant waiting list by making it easier for more people to be living donors,” said LaVarne A. Burton, president and CEO of the American Kidney Fund. “AKF has spearheaded efforts at the state level to pass living donor protections, working with state lawmakers to get such laws passed in 12 states. We are grateful to Reps. Nadler and Herrera Beutler, and Sens. Gillibrand and Cotton, for introducing legislation that will give people in every state the same baseline protections-ultimately saving the lives of people who are waiting for a transplant.”
The Living Donor Protection Act of 2021 (H.R.1255/S.377) would ensure that living organ donors have Family Medical Leave Act (FMLA) protections so they can take time off work to donate the kidney and recover from the surgery without fear of losing their job. The U.S. Department of Labor (DOL) issued an opinion letter in 2018 which stated that organ donation is protected under FMLA. The Living Donor Protection Act would codify the DOL opinion, protecting under federal statute those living donors whose employers are covered under FMLA.
The bill would also protect living donors from discrimination by insurance carriers and prohibits insurers from:
Declining or limiting coverage of a person under any life insurance policy, disability insurance policy, or long-term care insurance policy due to the person’s living donor status
Preventing a person from donating all or part of an organ as a condition of receiving a life insurance policy, disability insurance policy, or long-term care insurance policy;
Considering the fact that a person is a living organ donor when determining the premium amount.
About Us
The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.
Patient Finally Finds Relief Through Specialized Treatment Program at ReMed Pain and Wellness Clinic After Years of Suffering from Peripheral Neuropathy
Like more than 20 million other Americans, one of ReMed Pain and Wellness Clinic’s patients had been suffering from peripheral neuropathy for years. His feet would burn with numbness day in and day out, and nothing made it better. He was unable to sleep well because of the pain, nor was he able to live his normal life during the day thanks to the persistent stinging and burning.
He visited multiple medical clinics that specialized in treating neuropathy in the Dallas area seeking relief for his painful and numb feet. Despite undergoing dozens of treatments and taking his prescribed medications, the patient still felt almost no relief, and remained in continuous pain.
The patient was beyond frustrated, and became hopeless. He had even resigned to accept that he would never live his normal life again. It was at that time that he came across an ad for ReMed Pain and Wellness Clinic in the Dallas Morning News and decided to call them to see what they could do for him.
The medical professionals at ReMed explained the difference between their program and the failed ones the patient had already tried, and how Medicare insurance could cover the cost of his program. The patient made an appointment for an evaluation and the rest was history.
In just two months, the patient reports that his numbness is 85% gone and he has almost no burning in his feet whatsoever. In fact, he is now sleeping better and able to resume his daily activities for the first time in years.
What Other Services Does ReMed Pain and Wellness Clinic Provide?
As a multi-disciplinary clinic, ReMed has been treating patients who have suffered from injuries and accidents, as well as neuropathy, knee pain and other conditions since 1991. Some of the services provided are regenerative treatments such as platelet-rich plasma injections and regenerative tissue, as well as chiropractic care and rehabilitation therapy.
With a highly experienced team of doctors and medical professionals, ReMed is well-equipped to help patients deal with all types of injuries, whether auto accidents, on-the-job injuries, or other. Their focus is on helping the body to heal itself naturally, so patients can get back to doing the things they love to do.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m. ET, and will be available for virtual investor meetings.
A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of this webcast will be available for 60 days on the Company’s website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.